NFκB1: a common biomarker linking Alzheimer's and Parkinson's disease pathology
TNFα signaling through the NF-κB pathway was identified as a prominently dysregulated mechanism in both AD and PD samples. Transcript levels of NFE2L2 (NRF2) and NF-κB1 were elevated, coinciding with reduced expression of the mitochondrial transporter gene SLC25A6, suggesting a compensatory response to oxidative stress. Additionally, PLCG2 expression was markedly increased in microglial populations, reflecting heightened immune activation. A significant 10-fold reduction in hemoglobin subunit alpha (HbA1) RNA was observed in disease groups compared to controls, indicating compromised oxygen transport and cellular stress. These findings highlight candidate biomarkers and suggest that therapeutic strategies targeting mitochondrial integrity and neuroinflammation may be effective in AD and PD.
Authors
- Emma Barrett (ORCID: https://orcid.org/0000-0003-0762-5196)
- Prabir Patra (ORCID: https://orcid.org/0000-0002-2917-793X)
- Joon W. Shim (ORCID: https://orcid.org/0000-0002-5490-684X)
- Abhay Moghekar (ORCID: https://orcid.org/0000-0001-9464-1551)
- Adam Cunningham (ORCID: https://orcid.org/0000-0002-9791-7813)
- Peter H.U. Lee (ORCID: https://orcid.org/0000-0003-3202-857X)
- Chan Lee (ORCID: https://orcid.org/0000-0003-1654-4398)
- S. Craig Risch
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Johns Hopkins University (US)
- Brown University (US)
- SouthCoast Health (US)
- Marshall University (US)
Publication Details
- Journal
- Frontiers in Neuroscience
- Published
- 2025-05-06
- DOI
- https://doi.org/10.3389/fnins.2025.1589857
- Citations
- 6
- Primary Topic
- Nuclear Receptors and Signaling
- Type
- article
- Field-Weighted Citation Impact
- 5.45
Funders
- National Aeronautics and Space Administration
- West Virginia Clinical and Translational Science Institute
- Nuclear Safety and Security Commission
- National Institutes of Health